JPMorgan initiated coverage of Kailera Therapeutics (KLRA) with an Overweight rating and $30 price target Kailera is a biotech with four clinical-stage obesity medications in its pipeline, the analyst tells investors in a research note. The firm says the company has a broad portfolio, including both injectable and orals. It thinks weight loss from injectable ribupatide should exceed that from Zepbound.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRA:
- Kailera Therapeutics initiated with a Buy at Jefferies
- Opening Day: HawkEye 360 jumps in debut after high‑end pricing
- PMV Pharmaceuticals chair Rich Heyman to depart, Laurie Stelzer to succeed
- Opening Day: Drone maker AEVEX pops on debut
- Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market